In a report released today, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks, with a price target of $30.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Martin PhD has given his Buy rating due to a combination of factors related to Zymeworks’ promising clinical trial results. The Phase 3 HERIZON-GEA-01 study demonstrated that Ziihera, when combined with chemotherapy or with both tislelizumab and chemotherapy, showed statistically significant and clinically meaningful improvements in progression-free survival compared to the current standard of care.
Additionally, the combination of Ziihera with tislelizumab and chemotherapy also resulted in a significant overall survival benefit, while Ziihera with chemotherapy alone showed a strong trend towards improved overall survival. These positive outcomes suggest a strong potential for Ziihera in treating HER2-positive locally advanced or metastatic gastroesophageal cancer, supporting the Buy rating for Zymeworks’ stock.
In another report released today, Citi also maintained a Buy rating on the stock with a $35.00 price target.